From the Chairman/CEO
I am pleased to report solid results for the third quarter of 2009. Cephalon delivered strong growth of both sales and adjusted net income compared to the third quarter of 2008, despite the difficult economic environment. Our quarterly sales reached an impressive $535 million and adjusted net income exceeded the high end of our guidance.
We have added assets and expertise through business development activities that will help us build our business through the remainder of this year, and for the future . In August, we completed the acquisition of Arana Therapeutics, which reinforced our commitment to the area of inflammatory diseases, and provided us a firm footing in biologics. Our entry into the biologics space combined with our efforts with our small molecule products creates a strong pipeline of rich and diverse opportunities to address unmet medical needs.
We are Cephalon
A global biopharmaceutical company driven to expand the boundaries of science to improve human health. A company with first-in-class therapeutics, a rich oncology research pipeline and medications to treat central nervous system disorders, cancer, and pain. A company dedicated to our patients, healthcare professionals, employees, and communities.
Latest News
Cephalon signs option agreement to acquire BioAssets Development Corporation – deal will provide Cephalon with path forward in development of tumor necrosis factor inhibitor to treat sciatica.
Read press release>>
Oncology Nursing Society Foundation Partnership
Cephalon joins forces with the ONS Foundation to improve the lives of people with cancer. Read more >>
Cephalon to Match Employee Gifts to Earthquake Relief
Cephalon is responding to the earthquake disaster by encouraging employees to contribute to disaster relief efforts.Read more >>
Breakthrough Pain Awareness
Furthering our commitment to patient education about breakthrough pain associated with cancer. Read more >>
Michael Thorpy, M.B.,Ch.B., Professor of Clinical Neurology
On Cephalon’s commitment to the sleep community and people with sleep disorders. Read more >>
Bruce Cheson, M.D., Professor of Medicine
On the value of TREANDA for patients with relapsed indolent non-Hodgkin's lymphoma. Read more >>
Margaret Hansen Frogge, RN, MS, President, ONS Foundation
On the partnership between Cephalon and the Oncology Nursing Society (ONS) Foundation. Read more >>